The study aimed to evaluate the risk of developing anemia in older Danish individuals (aged 65 and above) who used low-dose aspirin (LDA) for cardiovascular prevention between 2008 and 2013.
Using Danish health registers, researchers tracked over 313,000 participants and found that LDA users had a significantly higher incidence of both hematinic deficiency (9.6%) and anemia (5.9%) compared to non-users.
The results suggest that approximately 6 to 10 out of every 100 older adults using LDA may develop anemia within the first five years of treatment, highlighting the risks associated with LDA usage in this demographic.